ClinicalTrials.gg
Not yet recruitingNCT06770881Updated Jan 13, 2025

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

A Phase 1/2 interventional study of JSKN033 in Advanced Malignant Tumors, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
430
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand form, voluntarily participate and sign informed consent form.
  2. Age ≥18 year (at the time consent is obtained), male or female.
  3. Has an (ECOG) performance status of 0-1.
  4. Has a ≥3 months.
  5. Has a documented advanced/unresectable or solid malignant tumor that is to or intolerable with standard treatment.
  6. Has at least 1 at baseline according to 1.1 criteria.
  7. Must have adequate organ function prior to the start of JSKN033.
  8. Negative urine/serum pregnancy test for females of who are sexually active with a non-sterilized male partner.

Exclusion criteria

Exclusion Criteria:

  1. Has clinically active .
  2. Previously received any other drug within 28 days prior to enrollment.
  3. Previously received local palliative treatment within 14 days prior to enrollment.
  4. Previously received major surgeries within 28 days prior to enrollment.
  5. Need to receive continuous administration of or for 7 days within 14 days prior to enrollment.
  6. Previously received within 28 days prior to enrollment.
  7. Previously received antibody conjugate drug with topoisomerase I inhibitor.
  8. Has a history of other primary malignant tumors within 5 years prior to enrollment.
  9. Has uncontrolled comorbidities as specified by the protocol.
  10. Has a history of interstitial pneumonia/lung disease requiring systemic hormonal therapy, or suspected interstitial pneumonia/lung disease that cannot be ruled out by imaging during screening period.
  11. Subjects with uncontrolled large serous cavity effusion or moderate to large serous cavity effusion requiring repeated drainage (recurrent within 2 weeks after intervention) such as pleural effusion, pericardial effusion, ascites, etc.
  12. Toxicities of previous antitumor therapy did not resolve to grade 1 defined by v5.0.
  13. Has a history of life-threatening anaphylaxis or known to any component or to the study drug.
  14. Has a history of allogeneic bone marrow or organ transplantation.
  15. Pregnant or breastfeeding female patients.
  16. Other conditions that the investigator considers unsuitable to participate in this clinical trial, including but not limited to psychiatric disorders, alcoholism or drug abuse, etc.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    JSKN033

    Drug: JSKN033

Interventions

  • JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Incidence of DLT in the dose escalation period.

    Time frame: Up to 12 months

  2. Maximum Tolerated Dose (MTD) or recommend Phase II dose (RP2D).

    Based on safety and efficacy data.

    Time frame: Up to 12 months

  3. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events (TEAE) and Treatment Related Adverse Events (TRAE)

    TEAE and TRAE were graded according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: Throughout the duration of the study, approximately 2 years

Secondary outcomes

  1. Anti-drug antibodies (ADA) and neutralizing antibodies

    Status (positive or negative) and serum titers of anti-JSKN033 antibody.

    Time frame: Throughout the duration of the study, about 2 years

  2. Objective response rate (ORR)

    ORR is determined by investigators based on RECIST 1.1 criteria.

    Time frame: Throughout the duration of the study, about 2 years

  3. Disease control rate (DCR)

    DCR is determined by investigators based on RECIST 1.1 criteria.

    Time frame: Throughout the duration of the study, about 2 years

  4. Progression-free survival (PFS)

    PFS is defined as the time from the date of the first dose to the earlier of the dates of the first objective documentation of radiographic disease progression or death due to any cause.

    Time frame: Throughout the duration of the study, about 2 years

  5. Maximum concentration (Cmax)

    Categories: JSKN003, total antibody (Tab) , payload of JSKN003 and envafolimab.

    Time frame: Throughout the duration of the study, about 2 years

  6. Time at which Cmax is reached (Tmax)

    Categories: JSKN003, total antibody (Tab) , payload of JSKN003 and envafolimab.

    Time frame: Throughout the duration of the study, about 2 years

  7. Area under the drug concentration-time curve (AUC) to the last observable concentration (AUClast)

    Categories: JSKN003, total antibody (Tab) , payload of JSKN003 and envafolimab.

    Time frame: Throughout the duration of the study, about 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2024
First posted
Jan 13, 2025
StartEst.
Jan 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06770881
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jan 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 13, 2025

Study contacts

XiaoHua Wu, MD
Contact
wu.xh@fudan.edu.cn
02134778299
Jian Zhang, MD
Contact
syner2000@163.com
02134778299
XiaoHua Wu, MD
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JSKN033

Start the discussion